Profound Medical Corp. (PROF)
NASDAQ: PROF · IEX Real-Time Price · USD
8.58
+0.11 (1.30%)
At close: Jul 2, 2024, 3:59 PM
8.64
+0.06 (0.70%)
After-hours: Jul 2, 2024, 4:00 PM EDT
Profound Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Profound Medical stock have an average target of 9.90, with a low estimate of 9.00 and a high estimate of 10.8. The average target predicts an increase of 15.38% from the current stock price of 8.58.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2024.
Analyst Ratings
The average analyst rating for PROF stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 2 | 2 | 2 | 2 | 2 | 1 |
Hold | 2 | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $13 → $11 | Strong Buy | Maintains | $13 → $11 | +25.87% | Mar 11, 2024 |
Stifel | Stifel | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +4.90% | Mar 8, 2024 |
Alliance Global Partners | Alliance Global Partners | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +48.60% | Jan 4, 2024 |
Stifel | Stifel | Hold Initiates $11 | Hold | Initiates | $11 | +28.21% | Nov 28, 2023 |
Raymond James | Raymond James | Strong Buy → Buy Downgrades n/a | Strong Buy → Buy | Downgrades | n/a | n/a | Aug 4, 2023 |
Financial Forecast
Revenue This Year
11.36M
from 7.20M
Increased by 57.79%
Revenue Next Year
33.52M
from 11.36M
Increased by 195.06%
EPS This Year
-1.16
from -1.35
EPS Next Year
-0.90
from -1.16
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 12.2M | 48.3M | 91.7M | 155.9M | 164.4M |
Avg | 11.4M | 33.5M | 54.0M | 99.6M | 106.7M |
Low | 10.8M | 24.9M | 34.8M | 43.8M | 53.7M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 69.2% | 325.2% | 173.5% | 188.8% | 64.9% |
Avg | 57.8% | 195.1% | 61.1% | 84.5% | 7.1% |
Low | 49.7% | 119.1% | 3.8% | -18.9% | -46.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | -1.18 | -0.90 | 0.34 | 1.93 |
Avg | -1.16 | -0.90 | -0.26 | 1.57 |
Low | -1.18 | -0.91 | -0.57 | 1.01 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|
High | - | - | - | - |
Avg | - | - | - | - |
Low | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.